
AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Dole, you need to believe in steady global demand for fresh produce and the company’s ability to manage thin margins in a capital intensive, weather exposed business. The tariff lawsuit and potential refund system touch the existing trade volatility risk, but for now they sit alongside, rather than replace, the more immediate pressures from extreme weather, commodity exposure, and a leveraged balance sheet as the near term swing factors.
The most relevant recent development here is Dole’s 2025 results, which showed US$9,172.91 million in sales and a much smaller Q4 loss than the prior year, alongside continued impairments and a modest dividend. Against that backdrop, any tariff refunds or changes to future import costs could affect how investors view the company’s ability to sustain earnings quality and cash returns while still investing in its farms, logistics, and infrastructure.
But while tariff relief might help in the short term, investors should also be aware that...
Read the full narrative on Dole (it's free!)
Dole's narrative projects $9.1 billion revenue and $163.0 million earnings by 2028.
Uncover how Dole's forecasts yield a $17.83 fair value, a 23% upside to its current price.
Some of the lowest ranked analysts were already cautious, assuming roughly flat revenues around US$9.0 billion and only gradual earnings growth by 2028, and this tariff focused uncertainty around trade policy and regulatory pressure could push their already more pessimistic view of Dole’s risk profile even further, so it is worth comparing these assumptions with your own expectations.
Explore 2 other fair value estimates on Dole - why the stock might be worth just $17.83!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com